Wuxi Huatai Innovative Pharmaceutical Technology Research Institute

Wuxi Huatai Innovative Pharmaceutical Technology Research Institute is a China-based biotechnology company focused on the discovery and development of innovative small molecule drugs for metabolic and endocrine diseases. Established in 2018 and headquartered in Wuxi, the institute leverages its internal R&D platform to advance a pipeline of candidates targeting high-prevalence conditions such as gout and non-alcoholic steatohepatitis (NASH). Its lead asset, HT-101, is a selective URAT1 inhibitor currently undergoing clinical evaluation for the treatment of hyperuricemia and gout. The company aims to address unmet medical needs through the development of highly potent and selective therapeutic agents.